[1]
|
Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Syste-mic Juvenile Idiopathic Arthritis[J]. Arthritis Rheumatol, 2022, 74: 553-569. doi: 10.1002/art.42037 |
[2]
|
Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging[J]. Arthritis Care Res (Hoboken), 2022, 74: 505-520. doi: 10.1002/acr.24839 |
[3]
|
Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis[J]. Arthritis Rheumatol, 2019, 71: 846-863. doi: 10.1002/art.40884 |
[4]
|
Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis[J]. Arthritis Rheumatol, 2019, 71: 864-877. doi: 10.1002/art.40885 |
[5]
|
Zulian F, Martini G, Gobber D, et al. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis[J]. Rheumatology (Oxford), 2003, 42: 1254-1259. doi: 10.1093/rheumatology/keg358 |
[6]
|
Zulian F, Martini G, Gobber D, et al. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial[J]. Rheumatology (Oxford), 2004, 43: 1288-1291. doi: 10.1093/rheumatology/keh313 |
[7]
|
Eberhard BA, Sison MC, Gottlieb BS, et al. Comparison of the intraarticular effectiveness of triamcinolone hexaceto-nide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis[J]. J Rheumatol, 2004, 31: 2507-2512. |
[8]
|
Wallace CA, Huang B, Bandeira M, et al. Patterns of clinical remission in select categories of juvenile idiopathic arthritis[J]. Arthritis Rheum, 2005, 52: 3554-3562. doi: 10.1002/art.21389 |
[9]
|
Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis[J]. Arthritis Care Res (Hoboken), 2011, 63: 929-936. doi: 10.1002/acr.20497 |
[10]
|
Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis[J]. Arthritis Rheum, 2009, 61: 658-666. doi: 10.1002/art.24516 |
[11]
|
McErlane F, Beresford MW, Baildam EM, et al. Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis[J]. Ann Rheum Dis, 2013, 72: 1983-1988. doi: 10.1136/annrheumdis-2012-202031 |
[12]
|
Tibaldi J, Pistorio A, Aldera E, et al. Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis[J]. Rheumatology (Oxford), 2020, 59: 3505-3514. doi: 10.1093/rheumatology/keaa240 |
[13]
|
Aikawa NE, Trudes G, Campos LM, et al. Immunogeni-city and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients[J]. Lupus, 2013, 22: 1394-1398. doi: 10.1177/0961203313505926 |
[14]
|
Toplak N, Subelj V, Kveder T, et al. Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis[J]. Clin Exp Rheumatol, 2012, 30: 436-444. |
[15]
|
Heijstek MW, Scherpenisse M, Groot N, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study[J]. Ann Rheum Dis, 2014, 73: 1500-1507. doi: 10.1136/annrheumdis-2013-203429 |
[16]
|
Heijstek MW, Kamphuis S, Armbrust W, et al. Effects of the live attenuated measles-mumps-rubella booster vaccina-tion on disease activity in patients with juvenile idiopathic arthritis: a randomized trial[J]. JAMA, 2013, 309: 2449-2456. doi: 10.1001/jama.2013.6768 |
[17]
|
Uziel Y, Moshe V, Onozo B, et al. Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection[J]. Vaccine, 2020, 38: 2198-2201. doi: 10.1016/j.vaccine.2020.01.037 |